Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
Purpose This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The primary endpoint was disease-free survival. Secondary endpoints included cardiac safety, tolerability, a...
Furkejuvvon:
| Váldodahkkit: | , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Korean Society of Surgical Oncology
2018-12-01
|
| Ráidu: | Korean Journal of Clinical Oncology |
| Fáttát: | |
| Liŋkkat: | http://www.kjco.org/upload/kjco-14-2-108.pdf |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|